CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
12.57
+0.19 (1.53%)
At close: Oct 24, 2024, 4:00 PM
11.94
-0.63 (-5.01%)
After-hours: Oct 24, 2024, 5:27 PM EDT
CervoMed Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for CervoMed stock have an average target of 57.6, with a low estimate of 35 and a high estimate of 70. The average target predicts an increase of 358.23% from the current stock price of 12.57.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 18, 2024.
Analyst Ratings
The average analyst rating for CervoMed stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 4 | 4 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $55 | Strong Buy | Initiates | $55 | +337.55% | Sep 18, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $35 | Buy | Initiates | $35 | +178.44% | Jul 26, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $65 | Strong Buy | Maintains | $65 | +417.10% | Jul 25, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $63 | Strong Buy | Initiates | $63 | +401.19% | Jul 8, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +456.88% | May 29, 2024 |
Financial Forecast
Revenue This Year
11.04M
from 7.14M
Increased by 54.54%
Revenue Next Year
4.08M
from 11.04M
Decreased by -63.05%
EPS This Year
-1.67
from -0.82
EPS Next Year
-3.02
from -1.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 13.0M | 7.1M | n/a | ||
| Avg | 11.0M | 4.1M | n/a | ||
| Low | 7.9M | 1.4M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 82.2% | -35.3% | - | ||
| Avg | 54.5% | -63.1% | - | ||
| Low | 11.1% | -87.6% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.66 | -2.51 | -3.09 | ||
| Avg | -1.67 | -3.02 | -4.20 | ||
| Low | -1.70 | -3.39 | -5.09 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.